C-reactive protein concentration predicts mortality in type 2 diabetes: the Diabetes Heart Study
Diabetic Medicine, 06/08/2012
Cox AJ et al. – This study documents the utility of C–reactive protein in predicting risk for all–cause mortality in European Americans with Type 2 diabetes and supports its use as a screening tool in risk prediction models.
A total of 846 European Americans with Type 2 diabetes and baseline measures of C-reactive protein were evaluated.
Vital status was determined after a follow-up period of 7.3 ± 2.1 years (mean ± SD).
C-reactive protein concentrations were compared between living and deceased subgroups along with other known risk factors for cardiovascular disease, including blood lipids.
Logistic regression was performed to determine risk for mortality associated with increasing C-reactive protein concentrations.
At follow-up 160 individuals (18.7%) were deceased.
No significant differences in baseline serum glucose or lipid measures were observed between living and deceased subgroups.
Baseline C-reactive protein concentrations were significantly higher in the deceased subgroup (9.37 ± 15.94) compared with the living subgroup (5.36 ± 7.91?mg/l; P < 0.0001).
Participants with C-reactive protein concentrations of 3-10 mg/l were approximately two times more likely to be deceased at follow-up (OR 2.06; 95% CI 1.17-3.62); those with C-reactive protein >10 mg/l were more than five times more likely to be deceased (OR 5.24; CI 2.80-9.38).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.